Phospho-PLD2 (Tyr169) Antibody | CSB-PA983138

Phospho-PLD2 (Tyr169) Antibody | CSB-PA983138 | Cusabio

Phospho-PLD2 (Tyr169) Antibody is Available at Gentaur Genprice with the fastest delivery.

Online Order Payment is possible or send quotation to info@gentaur.com.

Product Type: Polyclonal Antibody

Target Names: PLD2

Aliases: PLD 2; PLD1C; choline phosphatase 2;

Background:

Phosphatidylcholine (PC) -specific phospholipases D (PLDs) catalyze the hydrolysis of PC to produce phosphatidic acid and choline. Activation of PC-specific PLDs occurs as a consequence of agonist stimulation of both tyrosine kinase and G protein-coupled receptors. PC-specific PLDs have been proposed to function in regulated secretion, cytoskeletal reorganization, transcriptional regulation, and cell cycle control.

Steed P.M., FASEB J. 12:1309-1317 (1998) .
Lopez I., J. Biol. Chem. 273:12846-12852 (1998) .
Divecha N., EMBO J. 19:5440-5449 (2000) .

Isotype: IgG

Conjugate: Non-conjugated

Clonality: Polyclonal

Uniport ID: O14939

Host Species: Rabbit

Species Reactivity: Human, Mouse, Rat

Immunogen: Peptide sequence around phosphorylation site of tyrosine 169 (E-N-Y (p) -L-N) derived from Human PLD2.

Immunogen Species: Human

Applications: ELISA, WB, IHC

Tested Applications: ELISA, WB, IHC;WB:1:500-1:1000, IHC:1:50-1:100

Purification Method: Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy using non-phosphopeptide.

Dilution Ratio1: ELISA:1:2000-1:10000

Dilution Ratio2: WB:1:500-1:1000

Dilution Ratio3: IHC:1:50-1:100

Dilution Ratio4:

Dilution Ratio5:

Dilution Ratio6:

Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Form: liquid

Storage: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Initial Research Areas: Cardiovascular

Research Areas: Cancer;Cardiovascular;Metabolism;Signal transduction